|
1
|
Leemans CR, Braakhuis BJ and Brakenhoff
RH: The molecular biology of head and neck cancer. Nat Rev Cancer.
11:9–22. 2011. View
Article : Google Scholar
|
|
2
|
Greenlee RT, Hill-Harmon MB, Murray T and
Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patel SG and Shah JP: TNM staging of
cancers of the head and neck: striving for uniformity among
diversity. CA Cancer J Clin. 55:242–258. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shah NG, Trivedi TI, Tankshali RA, et al:
Prognostic significance of molecular markers in oral squamous cell
carcinoma: a multivariate analysis. Head Neck. 31:1544–1556. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Inui M, Martello G and Piccolo S: MicroRNA
control of signal transduction. Nat Rev Mol Cell Biol. 11:252–263.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartels CL and Tsongalis GJ: MicroRNAs:
novel biomarkers for human cancer. Clin Chem. 55:623–631. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jia LF, Wei SB, Gong K, Gan YH and Yu GY:
Prognostic implications of micoRNA miR-195 expression in human
tongue squamous cell carcinoma. PLoS One. 8:e566342013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li J, Huang H, Sun L, et al: MiR-21
indicates poor prognosis in tongue squamous cell carcinomas as an
apoptosis inhibitor. Clin Cancer Res. 15:3998–4008. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun L, Yao Y, Liu B, et al: MiR-200b and
miR-15b regulate chemotherapy-induced epithelial-mesenchymal
transition in human tongue cancer cells by targeting BMI1.
Oncogene. 31:432–445. 2012. View Article : Google Scholar
|
|
11
|
Siow M, Ng LK, Chong VV, et al:
Dysregulation of miR-31 and miR-375 expression is associated with
clinical outcomes in oral carcinoma. Oral Dis. 20:345–351. 2014.
View Article : Google Scholar
|
|
12
|
Harris T, Jimenez L, Kawachi N, et al:
Low-level expression of miR-375 correlates with poor outcome and
metastasis while altering the invasive properties of head and neck
squamous cell carcinomas. Am J Pathol. 180:917–928. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bell RB, Kademani D, Homer L, Dierks EJ
and Potter BE: Tongue cancer: Is there a difference in survival
compared with other subsites in the oral cavity. J Oral Maxillofac
Surg. 65:229–236. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shaw RJ, McGlashan G, Woolgar JA, et al:
Prognostic importance of site in squamous cell carcinoma of the
buccal mucosa. Br J Oral Maxillofac Surg. 47:356–359. 2009.
View Article : Google Scholar
|
|
15
|
Ding L, Xu Y, Zhang W, et al: MiR-375
frequently downregulated in gastric cancer inhibits cell
proliferation by targeting JAK2. Cell Res. 20:784–793. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou J, Song S, He S, et al: MicroRNA-375
targets PDK1 in pancreatic carcinoma and suppresses cell growth
through the Akt signaling pathway. Int J Mol Med. 33:950–956.
2014.PubMed/NCBI
|
|
17
|
Kong KL, Kwong DL, Chan TH, et al:
MicroRNA-375 inhibits tumour growth and metastasis in oesophageal
squamous cell carcinoma through repressing insulin-like growth
factor 1 receptor. Gut. 61:33–42. 2012. View Article : Google Scholar
|
|
18
|
Zhao H, Zhu L, Jin Y, Ji H, Yan X and Zhu
X: miR-375 is highly expressed and possibly transactivated by
achaete-scute complex homolog 1 in small-cell lung cancer cells.
Acta Biochim Biophys Sin. 44:177–182. 2012. View Article : Google Scholar
|
|
19
|
Wang F, Li Y, Zhou J, et al: miR-375 is
down-regulated in squamous cervical cancer and inhibits cell
migration and invasion via targeting transcription factor SP1. Am J
Pathol. 179:2580–2588. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagata D, Suzuki E, Nishimatsu H, et al:
Transcriptional activation of the cyclin D1 gene is mediated by
multiple cis-elements, including SP1 sites and a cAMP-responsive
element in vascular endothelial cells. J Biol Chem. 276:662–669.
2001. View Article : Google Scholar
|
|
21
|
Grinstein E, Jundt F, Weinert I, Wernet P
and Royer HD: Sp1 as G1 cell cycle phase specific transcription
factor in epithelial cells. Oncogene. 21:1485–1492. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu Y, Thomson JM, Wong HY, Hammond SM and
Hogan BL: Transgenic over-expression of the microRNA miR-17-92
cluster promotes proliferation and inhibits differentiation of lung
epithelial progenitor cells. Dev Biol. 310:442–453. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jia LF, Wei SB, Gan YH, et al: Expression,
regulation and roles of miR-26a and MEG3 in tongue squamous cell
carcinoma. Int J Cancer. 135:2282–2293. 2014. View Article : Google Scholar
|
|
24
|
Zhang WH, Gui JH, Wang CZ, et al: The
identification of miR-375 as a potential biomarker in distal
gastric adenocarcinoma. Oncol Res. 20:139–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Li X, Li Y, et al: Cell-specific
detection of miR-375 downregulation for predicting the prognosis of
esophageal squamous cell carcinoma by miRNA in situ hybridization.
PLoS One. 8:e535822013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Y, Jiang Q, Xia N, Yang H and Hu C:
Decreased expression of microRNA-375 in nonsmall cell lung cancer
and its clinical significance. J Int Med Res. 40:1662–1669. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu H, Jiang L, Sun C, et al: Decreased
circulating miR-375: a potential biomarker for patients with
non-small-cell lung cancer. Gene. 534:60–65. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chang C, Shi H, Wang C, et al: Correlation
of microRNA-375 downregulation with unfavorable clinical outcome of
patients with glioma. Neurosci Lett. 531:204–208. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Z, Hong Z, Gao F and Feng W:
Upregulation of microRNA-375 is associated with poor prognosis in
pediatric acute myeloid leukemia. Mol Cell Biochem. 383:59–65.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li H, Shang H, Shu D, et al: gga-miR-375
plays a key role in tumorigenesis post subgroup J avian leukosis
virus infection. PLoS One. 9:e908782014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Tang Q, Li M, Jiang S and Wang X:
MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.
Biochem Biophys Res Commun. 444:199–204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cawley S, Bekiranov S, Ng HH, et al:
Unbiased mapping of transcription factor binding sites along human
chromosomes 21 and 22 points to widespread regulation of noncoding
RNAs. Cell. 116:499–509. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Michinaga S, Ishida A, Takeuchi R and
Koyama Y: Endothelin-1 stimulates cyclin D1 expression in rat
cultured astrocytes via activation of Sp1. Neurochem Int. 63:25–34.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cram EJ, Liu BD, Bjeldanes LF and
Firestone GL: Indole-3-carbinol inhibits CDK6 expression in human
MCF-7 breast cancer cells by disrupting Sp1 transcription factor
interactions with a composite element in the CDK6 gene promoter. J
Biol Chem. 276:22332–22340. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baldin V, Lukas J, Marcote MJ, Pagano M
and Draetta G: Cyclin D1 is a nuclear protein required for cell
cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Motokura T, Keyomarsi K, Kronenberg HM and
Arnold A: Cloning and characterization of human cyclin D3, a cDNA
closely related in sequence to the PRAD1/cyclin D1 proto-oncogene.
J Biol Chem. 267:20412–20415. 1992.PubMed/NCBI
|
|
37
|
Bova RJ, Quinn DI, Nankervis JS, et al:
Cyclin D1 and p16INK4A expression predict reduced survival in
carcinoma of the anterior tongue. Clin Cancer Res. 5:2810–2819.
1999.PubMed/NCBI
|
|
38
|
Michalides R, van Veelen N, Hart A, Loftus
B, Wientjens E and Balm A: Overexpression of cyclin D1 correlates
with recurrence in a group of forty-seven operable squamous cell
carcinomas of the head and neck. Cancer Res. 55:975–978.
1995.PubMed/NCBI
|
|
39
|
Huang SF, Cheng SD, Chuang WY, et al:
Cyclin D1 overexpression and poor clinical outcomes in Taiwanese
oral cavity squamous cell carcinoma. World J Surg Oncol. 10:402012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chang YC, Illenye S and Heintz NH:
Cooperation of E2F-p130 and Sp1-pRb complexes in repression of the
Chinese hamster dhfr gene. Mol Cell Biol. 21:1121–1131. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim SJ, Onwuta US, Lee YI, Li R, Botchan
MR and Robbins PD: The retinoblastoma gene product regulates
Sp1-mediated transcription. Mol Cell Biol. 12:2455–2463.
1992.PubMed/NCBI
|
|
42
|
Datta PK, Raychaudhuri P and Bagchi S:
Association of p107 with Sp1: genetically separable regions of p107
are involved in regulation of E2F- and Sp1-dependent transcription.
Mol Cell Biol. 15:5444–5452. 1995.PubMed/NCBI
|
|
43
|
Karlseder J, Rotheneder H and
Wintersberger E: Interaction of Sp1 with the growth- and cell
cycle-regulated transcription factor E2F. Mol Cell Biol.
16:1659–1667. 1996.PubMed/NCBI
|
|
44
|
Gualberto A and Baldwin AS Jr: p53 and Sp1
interact and cooperate in the tumor necrosis factor-induced
transcriptional activation of the HIV-1 long terminal repeat. J
Biol Chem. 270:19680–19683. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Johnson-Pais T, Degnin C and Thayer MJ:
pRB induces Sp1 activity by relieving inhibition mediated by MDM2.
Proc Natl Acad Sci USA. 98:2211–2216. 2001. View Article : Google Scholar : PubMed/NCBI
|
